| scholarly article | Q13442814 |
| P356 | DOI | 10.1164/RCCM.200812-1927UP |
| P8608 | Fatcat ID | release_squgrbe7o5hgzamexa2figakcq |
| P698 | PubMed publication ID | 19264980 |
| P50 | author | Felix Ratjen | Q42421759 |
| P2860 | cites work | Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis | Q22306312 |
| The Pseudomonas toxin pyocyanin inhibits the dual oxidase-based antimicrobial system as it imposes oxidative stress on airway epithelial cells | Q24657390 | ||
| Sputum proteomics in inflammatory and suppurative respiratory diseases | Q33345110 | ||
| PTC124 targets genetic disorders caused by nonsense mutations | Q34003720 | ||
| Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation | Q34157044 | ||
| Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. | Q34750259 | ||
| Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. | Q35536357 | ||
| Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests | Q36166307 | ||
| Airway smooth muscle in bronchial tone, inflammation, and remodeling: basic knowledge to clinical relevance | Q36414879 | ||
| Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. | Q36924692 | ||
| Potential role of high-mobility group box 1 in cystic fibrosis airway disease. | Q36935244 | ||
| Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs | Q36944556 | ||
| Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung disease | Q36960790 | ||
| Role of mechanical stress in regulating airway surface hydration and mucus clearance rates | Q37104802 | ||
| characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling | Q37597340 | ||
| Inhaled mannitol improves lung function in cystic fibrosis. | Q38391625 | ||
| The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis | Q38453923 | ||
| Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect | Q40059104 | ||
| Recent advances in cystic fibrosis. | Q40085939 | ||
| Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis | Q40104046 | ||
| Role of sphingosine-1-phosphate phosphohydrolase 1 in the regulation of resistance artery tone | Q41883393 | ||
| Development of chronic bronchitis and emphysema in beta-epithelial Na+ channel-overexpressing mice. | Q43090504 | ||
| Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis | Q45874711 | ||
| Amiloride: still a viable treatment option in cystic fibrosis? | Q46218606 | ||
| Prevalence of low bone mass and deficiencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers | Q46269234 | ||
| Persistent osteopenia in adult cystic fibrosis transmembrane conductance regulator-deficient mice | Q46278772 | ||
| Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. | Q46320247 | ||
| Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial | Q46415131 | ||
| Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis | Q46453243 | ||
| Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis | Q46897526 | ||
| Mechanisms of cystic fibrosis transmembrane conductance regulator activation by S-nitrosoglutathione | Q46899977 | ||
| Impairment of apoptotic cell engulfment by pyocyanin, a toxic metabolite of Pseudomonas aeruginosa. | Q46966094 | ||
| The evolution of airway function in early childhood following clinical diagnosis of cystic fibrosis. | Q47228956 | ||
| Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis | Q47695927 | ||
| Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. | Q51021959 | ||
| Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. | Q51104440 | ||
| Detection of Anaerobic Bacteria in High Numbers in Sputum from Patients with Cystic Fibrosis | Q57913654 | ||
| Lung Function in Infants with Cystic Fibrosis Diagnosed by Newborn Screening | Q58385293 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| P304 | page(s) | 445-448 | |
| P577 | publication date | 2009-03-01 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Update in cystic fibrosis 2008. | |
| P478 | volume | 179 |
| Q47729413 | Attitudes Toward Discussing Approved and Investigational Treatments for Cystic Fibrosis in Prenatal Genetic Counseling Practice |
| Q37775620 | Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis |
| Q92901904 | Clinical Outcomes Associated With Escherichia coli Infections in Adults With Cystic Fibrosis: A Cohort Study |
| Q39022011 | Genetic, cell biological, and clinical interrogation of the CFTR mutation c.3700 A>G (p.Ile1234Val) informs strategies for future medical intervention. |
| Q26829604 | Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis |
| Q37940005 | Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis |
| Q38358856 | Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis |
Search more.